Non-Executive Chairperson

Dr John Fox brings over 30 years of drug development experience to his role as Non-Executive Chairperson of SignaCor. With a career spanning multinational pharmaceutical and biotech companies, he has led R&D initiatives from early-stage translation to late-phase clinical development. Dr Fox previously served as Chief Development Officer and CEO at Merrion Pharmaceuticals plc, and co-founded Hunter Fleming, a neuroprotection-focused biotech that advanced multiple assets into clinical trials before being acquired. His expertise covers a broad range of therapeutic areas including CNS, oncology, metabolic bone disease, and renal disorders. In addition to executive roles, Dr Fox has contributed as a non-executive director and advisor to emerging ventures in the UK and Ireland. He holds a PhD from Queen’s University Belfast and an MBA from Henley Management College, and is a member of the the Institute of Directors (UK).